DSIP (Delta Sleep-Inducing Peptide): Research Overview, Mechanisms, and Current Evidence
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first described in 1977 and named for its association with slow-wave (delta) sleep. It has been studied primarily in preclinical models for effects on sleep architecture, stress resilience, and neuroprotection. Most of the research is decades old and conducted in animals, with limited modern human data. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
DSIP's mechanism is not fully defined. In preclinical studies it has been reported to act on the central nervous system in the following ways.
- Crosses the blood-brain barrier, as documented in transport studies.
- Modulates neurotransmitters associated with sleep, including serotonin (5-HT), glutamate, dopamine, and melatonin, in insomnia models.
- Influences slow-wave sleep architecture in animal recordings.
- Some sleep-related effects are reversed by the opioid antagonist naloxone, suggesting opioidergic involvement.
Areas of Research Interest
Published studies have examined DSIP in the following research contexts. The evidence base is almost entirely preclinical.
Sleep modulation
Studied for effects on slow-wave sleep and sleep architecture in animal insomnia models.
Stress and memory
Examined for effects on stress responses and memory, including under high-altitude hypoxia in animal models.
Neuroprotection
Investigated in animal stroke models for effects on motor recovery and tissue protection.
Cardioprotection
DSIP-related analogs have been studied in models of myocardial and cerebral ischemia-reperfusion.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in specific published studies, with sources. It describes what researchers administered in these models and is not a protocol, recommendation, or guidance for use in humans or animals. Animal-study doses are expressed per kilogram of body weight.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Focal stroke, motor recovery (rat) | ~120 µg/kg, intranasal, 8 days | Tukhovskaya 2021·DOI |
| Sleep and memory at altitude (rat, phosphorylated DSIP) | ~10 µg/kg, intraperitoneal | Roy 2018·DOI |
| Human research | Limited historical data; no validated regimen established | Rahman 2026 |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2024 to 2026)
Recent peer-reviewed literature indexed on PubMed continues to revisit DSIP, mostly through analogs and delivery improvements, while noting the absence of clinical trials.
Recovery peptides in orthopaedics
A 2026 review groups DSIP among recovery peptides that target circadian and mitochondrial regulators, concluding that preclinical findings are promising but clinical trials are lacking. PubMed·DOI
Sleep and neurotransmitter balance
A 2024 study of a DSIP fusion peptide designed to cross the blood-brain barrier reported improved sleep measures and rebalanced neurotransmitter levels in a chemically induced insomnia mouse model. PubMed·DOI
Motor recovery after stroke
A 2021 rat study reported that intranasal DSIP administered before and after experimental stroke accelerated recovery of motor function, though the reduction in infarct volume was not statistically significant. PubMed·DOI
Sleep architecture and memory under hypoxia
A 2018 study reported that a phosphorylated form of DSIP improved sleep architecture and restored spatial memory in rats exposed to simulated high-altitude hypoxia, with effects linked to opioidergic signaling. PubMed·DOI
Research Questions
What is DSIP studied for?
In the literature, DSIP is studied mainly for effects on sleep architecture, stress responses, and neuroprotection, primarily in animal models.
What is the current state of human evidence?
Human research is limited and largely historical. No modern validated regimen exists, and reviewers note the absence of clinical trials.
How is it thought to work?
DSIP can cross the blood-brain barrier and has been reported to influence sleep-related neurotransmitters and slow-wave sleep, with some evidence of opioidergic involvement. Its full mechanism is not established.
Referenced Citations
Literature indexed on PubMed.
- Rahman, O.F., et al. (2026). Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J. Am. Acad. Orthop. Surg. Glob. Res. Rev., 10(1). PubMed·DOI
- Mu, X., et al. (2024). DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Front. Pharmacol., 15, 1439536. PubMed·DOI
- Tukhovskaya, E.A., et al. (2021). Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules, 26(17), 5173. PubMed·DOI
- Tukhovskaya, E.A., et al. (2021). DSIP-Like KND Peptide Reduces Brain and Myocardial Infarction during Reperfusion. Biomedicines, 9(4), 407. PubMed·DOI
- Roy, K., et al. (2018). Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude. Life Sci., 209, 282-290. PubMed·DOI
- Banks, W.A. (2015). Peptides and the blood-brain barrier. Peptides, 72, 16-19. PubMed·DOI
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.